Pfizer Inc

PFE

23.870USD

-0.980-3.94%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

47 / 176

Overall Ranking

157 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 27 analysts

Hold

Current Rating

29.130

Target Price

+22.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.

Fairly Valued

The company’s latest PE is 12.60, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.85B shares, decreasing 2.26% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 530.68M shares of this stock.

The company's current financial score is 8.18, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 13.71B, representing a year-over-year decrease of 7.82%, while its net profit experienced a year-over-year decrease of 4.75%.

Score

Industry at a Glance

Previous score

8.18

Change

0



Financials

7.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.85

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.10

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 13.23, which is 29.83% below the recent high of 17.17 and 40.57% above the recent low of 7.86.

Score

Industry at a Glance

Previous score

5.26

Change

0.03

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/176

No Data

The company’s current earnings forecast score is 6.88, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for Pfizer Inc is 28.00, with a high of 41.49 and a low of 24.00.

Score

Industry at a Glance

Previous score

6.96

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.27, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 26.42 and the support level at 23.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.18

Change

-0.09

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 67.75%, representing a quarter-over-quarter decrease of 0.23%. The largest institutional shareholder is The Vanguard, holding a total of 530.68M shares, representing 9.33% of shares outstanding, with 2.51% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

520.58M

+0.89%

State Street Global Advisors (US)

296.97M

+2.23%

BlackRock Institutional Trust Company, N.A.

291.55M

+4.29%

Geode Capital Management, L.L.C.

125.65M

+4.20%

Norges Bank Investment Management (NBIM)

87.79M

+4.55%

Wellington Management Company, LLP

103.49M

-26.07%

MFS Investment Management

73.03M

-1.60%

State Farm Insurance Companies

57.75M

+0.86%

BlackRock Asset Management Ireland Limited

50.47M

+9.83%

Charles Schwab Investment Management, Inc.

48.03M

-69.10%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.37, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Pfizer Inc

PFE

6.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.